APIRx Pharmaceuticals, BV CPhI Worldwide, October 9-11, 2018 Madrid, Spain
APIRx Pharma • Cannabis sativa contains 145 identified chemical compounds known as cannabinoids. Several of these compounds demonstrate biological activities. • APIRx is the world’ first manufacturer of pharma -quality cGMP cannabinoid API’s from cannabis plant: • THC (tetrahydrocannabinol) • CBD (cannabidiol) • CBG (cannabigerol) • We use cannabis supplied by Bedrocan BV, which cultivates the plant according to GMP conditions. • We are in a process of filing DMF’s in the US, Canada, as well as CEP in Europe.
Tetrahydrocannabinol (T (THC) THC was first isolated from cannabis plant in 1964 by Raphael Mechoulam and Yechiel Gaoni at the Weitzman Institute of Science in Israel. THC is scheduled by the UN Convention on Psychotropic Substances. It was listed under Schedule I in 1971, but reclassified to Schedule II in 1991. In the US THC is listed as a Sch I controlled substance by US federal law under the Controlled Substance Act. Synthetic THC is used in the US in an antiemetic drug; Marinol and its generic versions (dronabinol), and natural THC is used in a drug Nabiximols (Sativex ), which has been registered in a number of countries to treat spasticity in MS.
Cannabidiol (C (CBD) CBD was isolated from cannabis in 1940 independently by Adams and Todd and their colleagues. The chemical structure of CBD was fully established in 1963 by Mechoulam and Shvo. CBD does not appear to have any psychotropic ("high") effects such as those caused by THC and is not listed in the UN Convention on Psychotropic Substances. In the US CBD is schedule I (CI) controlled substance, while outside the US its legal status varies from country to country. CBD is one of two active ingredients in a drug Sativex and was recently approved by the USFDA as Epidolex for rare types of childhood epilepsy (Dravet, Lennox-Gastaut, Tuberous Sclerosis) as a sole API. DEA scheduled Epidolex as CV controlled drug.
Cannabigerol (C (CBG) Cannabigerol is a minor constituent of cannabis. During plant growth, most of the CBG is converted into other cannabinoids, primarily THC and CBD, usually leaving below 1% CBG in the plant. CBG is not listed in the UN Convention on Psychotropic Substances. Research is limited, including laboratory models of colitis, neurodegeneration, cancer, infectious diseases (MRSA, MDRB), dermatological conditions and feeding behavior as well as some other diseases and conditions where it demonstrated promising results. CBG has been shown to promote apoptosis in cancer cells (Colon CA) and inhibit tumor growth in vivo and in vitro.
Cannabinoids • Cannabis have been used for medical purposes for over 4000 years; first in China and India then in Egypt and Mediterranean region and since the 16th century in Europe. • Individual cannabinoids were first isolated and characterized in Israel in mid 1960’s by Professor Raphael Mechoulam (Hebrew University, Jerusalem). • In 1990’s Professor Mechoulam and his colleagues discovered and identified the endocannabinoid system which participates in all physiological processes in human, animal and primitive organisms. • This opened up an opportunity of using cannabinoids for treating multiple disorders and symptoms.
The Endocannabinoid System • Endocannabinoids and their receptors are found throughout the body: in the brain, all organs, connective tissues, glands, immune cells, etc. In each tissue, the ECS performs different tasks, but the goal is always the same: homeostasis, the maintenance of a stable internal environment despite fluctuations in the external environment. • Cannabinoids promote homeostasis at every level of biological life; from the sub‐cellular, to the organism, and beyond. Endocannabinoids and cannabinoids are found at the intersection of the body's various systems allowing communication and coordination between different cell types. • At the site of an injury, cannabinoids can be found decreasing the release of activators and sensitizers from the injured tissue, stabilizing the nerve cell to prevent excessive firing, and calming nearby immune cells to prevent release of pro‐inflammatory substances, thus being neuroprotective.
Cannabinoid’ Potential Therapeutic Applications
Potential Therapeutic Use of Cannabinoids Glioma Osteoporosis Tourette’s Syndrome Alzheimer’ s ALS HIV Fibromyalgia MRSA Hypertension Dystonia MS Sleep Apnea Hepatitis C Chronic Pain Incontinence Diabetes IBS Rheumatoid Arthritis Pruritus IBD Reproductive
Cannabinoids in USA • The very first cannabinoid drug ( Marinol ) was approved in the USA in 1985. This drug product and its generic versions are soft gelatin capsules containing synthetic THC dissolved in sesame oil. The drug is used predominantly as an antiemetic in cancer patients to suppress nausea and vomiting resulting from chemotherapy and loss of appetite/ weight loss in HIV/ AIDS. • Syndros , a synthetic THC oral solution (in sesame oil) has also been approved for the same indication. • Several drug candidates containing synthetic CBD are being developed in the US.
Cannabinoids in USA and Beyond • In April of 2018 FDA approved the first drug which contained plant derived CBD – Epidolex . • In the countries outside the US which include Israel, Canada, Spain, Germany, etc. plant-derived cannabinoids are used in drug development projects. • The first drug which contains THC and CBD ( Sativex ) has been approved by the EMA and in more than 30 countries worldwide. • So far, cGMP plant-derived cannabinoids were not commercially available on the market.
In Inquiries, Samples and Shipment Should you need a sample or supply of cannabinoid API’s which we offer, APIRx can ship the samples or commercial quantities of the material after a customer provides an original import permit issued in the country where the material needs to be shipped. Visit our website: WWW.APIRXPHARMA.COM
Investor Presentation December 2018 Company Overview Engaged in manufacturing and marketing of diverse Operates as a Contract Manufacturer (CMO) range of pharmaceutical products: Oral Solids, Oral for leading Multinational Pharmaceutical
328 views • 22 slides
Company Name: Corbus Pharmaceuticals Holdings Inc. (CRBP) Event: 2016 JMP Securities Life Sciences Conference Date: June 22, 2016 <<Liisa A. Bayko, Analyst, JMP Securities>> I want to welcome Corbus to our conference. And Yuval
269 views • 10 slides
11/23/17 The Policemans Dilemma House of Lords National Mental Capacity Forum An isolated highway Portraying assisted suicide and Fuel tanker overturns euthanasia Driver trapped in the cab A policeman patrol car arrives at the scene
458 views • 4 slides
Enhanced Community Palliative Support Services Lynne Ghasemi St Lukes Hospice Learning Outcomes Define the different types of pain Describe the process of pain assessment Discuss pharmacological management of pain Identify non
746 views • 28 slides
Cannabis In Health & Disease Presented at Omnilore Forum January 31, 2019 Rancho Palos Verdes, California David Bearman, MD Executive VP, AACM Santa Barbara, California www.davidbearmanmd.com Presentation Overview Introduction
929 views • 92 slides
10/10/2019 The story of courageous Jackson. Little wonder & typically developing, Jackson Leyden, with his dad John, prepping for baby brother! Courageous Jackson with mom, Lisa. On the journey with epilepsy. Pediatrics & We are
739 views • 20 slides
7/29/2014 Winship Brain Tumor Center of Emory University New Treatment Approaches for Glioblastoma Costas G. Hadjipanayis, MD, PhD Associate Professor of Neurosurgery Director, Winship Brain Tumor Center Chief of Neurosurgery, Emory University
618 views • 25 slides
www.thcl.com.au ASX RELEASE (6 th June 2017) UPDATED INVESTOR PRESENTATION The Hydroponics Company (ASX:THC), in accordance with ASX Listing Rule 3.1, provides an updated Investor Presentation. This presentation is being used for current
324 views • 19 slides
Biliary System: Anatomy and Physiology Review Katherine Mansfield RN,CGN,MN Clinical Nurse Educator St Michaels Hospital Objectives To review the anatomy and physiology of the Biliary System To consider the main functions of the
757 views • 46 slides
Lexaria Bioscience Corp. Investor Presentation October 2016 CSE:LXX; OCTQB:LXRP www.lexariaenergy.com 1 Disclaimer This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
289 views • 17 slides
ASX:THC A l e a d i n g , g l o b a l c a n n a b i s b u s i n e s s Investor Presentation June 2017 DISCLAIMER The material in this presentation ( ma material ) is not and does not Such statements relate to future events and expectations
475 views • 18 slides
9/30/2018 1 9/30/2018 Audits: How to Protect Your Bottom Line NCPA 2018 Annual Convention Amanda Gaddy, RPh Director of Clinical Services Georgia Pharmacy Association Disclosure Amanda Gaddy is a pharmacy consultant and is receiving an
334 views • 15 slides
Avoiding Chemical Slavery Introduction 1. Understand basic definitions of substance dependence/abuse 2. How substance dependence works Objec ectives es 3. How substance dependence affects learning 4. Specific on marijuana Substance
959 views • 64 slides
The CHARTS GROUP 2017 MDS, CMS & REGULATORY UPDATES NELIA ADACI RN, BSN CDONA, C-NE, RAC-CT VICE PRESIDENT QUOTES ABOUT CHANGE The first step toward change is awareness. The second step is acceptance . - Nathaniel Branden
1.26k views • 90 slides
Community Engagement in Providing Palliative Care in Rural and Regional Areas I am incredibly nervous about addressing a group of health care professionals with better credentials in palliative care than I, and nervous that my emotions will
674 views • 10 slides
Professor Fiona McQueen Chief Nursing Officer Scottish Government Supporting the best start.the best journey If not us.. Vision Programme for Government Increasing income in lowest three deciles Reducing depopulation of rural
697 views • 54 slides
Patent Protection for Three- Dimensional Structure of Protein Genomic Science Center, RIKEN Itsuki Shimbo Protein structure analysis and Industrial utilization A data array comprising the atomic coordinates of protein "inventions
642 views • 10 slides
1 Antigen Presenting Cells, Antigen Presentation, T Lymphocyte Activation Abul K. Abbas UCSF FOCiS 2 Lecture outline Dendritic cells and antigen presentation The role of the MHC T cell activation Costimulation, the B7:CD28
954 views • 28 slides
1 Dendritic Cells, Antigen Presentation, T Lymphocyte Activation Abul K. Abbas UCSF FOCiS 2 Lecture outline Dendritic cells and antigen presentation The role of the MHC T cell activation Costimulation, the B7:CD28 family 3
836 views • 26 slides
September 16, 2013 SCIENCE SPOTLIGHT No Nove vel l Mech Mechanism anism of of Ex Extr trac acellul ellular An ar Antigen tigen Cro Cross ss- Present Presentat atio ion September 16, 2013 VA Morris The ability of the immune
283 views • 3 slides
Histol Histopathol (1 996) 11 : 267-274 Histology and Histopathology ln vited Re vie w Principies of MHC class 1-mediated antigen presentation and T cell selection H.-G. Ljunggren and C.J. Thorpe Microbiology and Tumor Biology Center,
295 views • 8 slides
CART Global Program Team, Global Drug Development, Novartis Pharmaceuticals Co Chimeric Antigen Receptor (CAR)-T cells David Lebwohl, MD, Sr. VP and Global Program Head, CART Novartis London, UK November 15, 2016 Disclaimer This
525 views • 38 slides
4 The challenge for lymphocytes Very few lymphocytes in the body are specific for any one microbe (or antigen) Specificity and diversity of antigen receptors: the immune system recognizes and distinguishes between 10 6 - 10 9 antigens;
360 views • 12 slides
Campylobacteriosis Laboratory Testing Lucy Frederick Florida Department of Health Summer Intern Leah Eisenstein, M.P.H. Janet J. Hamilton, M.P.H. 1 2011 Cases Report date= Jan 1, 2011 to June 27, 2011 1,056 reported cases of
333 views • 10 slides